Advertisement


Robert J. Motzer, MD, on Renal Cell Carcinoma: New Results With Nivolumab and Ipilimumab

ESMO Congress 2022

Advertisement

Robert J. Motzer, MD, of Memorial Sloan Kettering Cancer Center, discusses phase III results of the CheckMate 914 trial, which explored the efficacy of adjuvant nivolumab plus ipilimumab vs placebo in the treatment of patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (Abstract LBA4).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The CheckMate 914 trial compared nivolumab plus ipilimumab to placebo in patients who had undergone a nephrectomy for clear cell carcinoma and were at substantial risk of recurrence. The eligibility included patients who were pT2a high grade, any pT2b, any pT3, pT4, or N1 positive disease, and the patients were randomized one to one to Nivolumab, 240 mg IV every two weeks for 12 doses, ipilumumab 1 mg/kg IV every six weeks for four doses or matched placebo. The expected treatment duration of this study was six months. The trial randomized over 800 patients and the patient characteristics were quite balanced. The majority of patients, nearly 80%, fell into the pT3a category. The primary endpoint of the trial was disease-free survival by blind, independent central review, and at the time of the analysis, the trial did not reach the primary endpoint. The hazard ratio for comparison between the two arms was 0.92, and the P value was 0.53. The 24-month disease-free survival rate was 76% for NIVO plus IPI, and 74% for placebo. The adverse event profile for NIVO plus IPI was similar to that, which we had seen in the studying of advanced disease. However, few patients, relatively few, completed the full 12 courses of NIVO and four of IPI, only 57%. The proportion of patients that had treatment-related grade three or higher AEs was 28% for NIVO plus IPI, compared to 2% per placebo. This is actually a lower rate than we saw for NIVO plus IPI in the setting of metastatic disease, but the treatment discontinuation rate was relatively high in this trial in the adjuvant setting. Treatment adverse events were as expected. The most common was pruritus, fatigue, and diarrhea, as we'd expect for NIVO plus IPI, and the proportion of patients who required high dose steroids on this NIVO plus IPI program was 23%. In summary then, part A of CheckMate 914 trial, which compares NIVO plus IPI to placebo in patients with localized RCC at high risk of post-nephrectomy relapse did not meet the primary endpoint of disease-free survival. The safety profile of NIVO plus IPI was consistent with the known profile for the combination of advanced RCC. However, the rate of discontinuation due to treatment-related adverse events was considerable with NIVO plus IPI in the adjuvant setting. Further analysis underway to understand the outcome of CheckMate 914 with regard to the patient population studied, and there is a part B, which is essentially a separate trial that has a primary endpoint of comparing NIVO monotherapy to placebo. That study is ongoing.

Related Videos

Breast Cancer
Genomics/Genetics

Antonio Marra, MD, on Metastatic Breast Cancer: Patterns of Genomic Instability and Their Effect on Treatment

Antonio Marra, MD, of Memorial Sloan Kettering Cancer Center, discusses a mutational signature analysis that reveals patterns of genomic instability linked to resistance to endocrine therapy with or without CDK4/6 inhibition in patients with estrogen receptor–positive/HER2-negative metastatic breast cancer (Abstract 210O).

Kidney Cancer

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Review of Two Key Abstracts on Belzutifan Plus Cabozantinib and Pembrolizumab Plus Lenvatinib

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss results from two important trials presented at ESMO 2022: Cohort 1 of the LITESPARK-003 study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC), and the KEYNOTE-B61 study of pembrolizumab plus lenvatinib as first-line treatment for non–clear cell RCC (Abstracts 1447O and 1448O).

Pancreatic Cancer

Christelle de la Fouchardiere, MD, on Pancreatic Ductal Adenocarcinoma: Phase III Trial Results With Gemcitabine Plus Paclitaxel

Christelle de la Fouchardiere, MD, of France’s Centre Léon Bérard, discusses phase III findings from the PRODIGE 65–UCGI 36–GEMPAX UNICANCER study, which evaluated whether the combination of gemcitabine and paclitaxel improves overall survival compared with gemcitabine alone in patients with metastatic pancreatic ductal adenocarcinoma after FOLFIRINOX failure or intolerance (Abstract LBA60).

Breast Cancer

Matthew P. Goetz, MD, on Breast Cancer: Interim Survival Results With Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor

Matthew P. Goetz, MD, of Mayo Clinic, discusses recent data from the MONARCH 3 trial of patients with advanced hormone receptor–positive, HER2-negative breast cancer. The study, a second interim analysis, showed that longer overall survival was observed in both the intention-to-treat group as well as in the subgroup with visceral disease. However, neither met the threshold for statistical significance, and further analyses are planned when more data can be reported. (Abstract LBA15).

Solid Tumors

Bernd Kasper, MD, PhD, on Desmoid Tumors: Results on Nirogacestat vs Placebo

Bernd Kasper, MD, PhD, of Germany’s Mannheim Cancer Center, discusses phase III data from the DeFi trial, the largest study conducted to date for patients with desmoid tumors. The trial showed that the gamma secretase inhibitor nirogacestat demonstrated improvements in all primary and secondary efficacy endpoints. Although considered benign because of their inability to metastasize, desmoid tumors can cause significant morbidity and, occasionally, mortality in patients (Abstract LBA2).

Advertisement

Advertisement




Advertisement